An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial. [electronic resource]
Producer: 20171221Description: 1672-9 p. digitalISSN:- 1499-2752
- Adult
- Aged
- Anti-Inflammatory Agents, Non-Steroidal -- adverse effects
- Dose-Response Relationship, Drug
- Drug Therapy, Combination
- Female
- Humans
- Lung Diseases, Interstitial -- drug therapy
- Male
- Middle Aged
- Mycophenolic Acid -- therapeutic use
- Pyridones -- adverse effects
- Scleroderma, Systemic -- complications
- Treatment Outcome
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.